Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 10/20 | 0.43 |
| ▸ | CTSS | P25774 | 4/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 2/20 | 0.37 |
| ▸ | CTSB | P07858 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1968178 | 1.00 | CYP2D6 (0.47) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL344731 | 0.87 | CYP2D6 (0.55) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL29990821 | 0.87 | CYP2D6 (0.55) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL168389 | 0.87 | CYP2D6 (0.55) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL3689498 | 0.87 | CYP2D6 (0.55) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL272149 | 0.85 | CYP2D6 (0.46) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL14489658 | 0.85 | CYP2D6 (0.46) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL272147 | 0.85 | CYP2D6 (0.46) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL4747461 | 0.84 | CYP2D6 (0.53) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL8972192 | 0.82 | CYP2D6 (0.50) | CYP2D6CA1CA2CA7CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2230238-B1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG LIFE SCIENCES LTD (KR) | 2013-12-11 | — | — | EP | disclosed |
| US-8349885-B2 | Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect | LG LIFE SCIENCES LTD. (KR) | 2013-01-08 | — | — | US | disclosed |
| US-20120270203-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG CHEM, LTD. (KR) | 2012-10-25 | — | — | US | disclosed |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| EP-2334689-A2 | FUSED HETEROCYCLIC COMPOUND | LG Life Sciences Ltd. (KR) | 2011-06-22 | — | — | EP | disclosed |
| US-20100291533-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG LIFE SCIENCES LTD. (KR) | 2010-11-18 | — | — | US | disclosed |
| EP-2230238-A2 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG Life Sciences Ltd. (KR) | 2010-09-22 | — | — | EP | disclosed |
| WO-2010027236-A2 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270203-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | IDO1, IDO2, INMT | CYP2D6 1186/4885CA1 949/4885CA2 1053/4885 |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | F2, PF4, F11 | CYP2D6 1195/4885CA1 3713/4885CA2 2272/4885 |
| US-20100291533-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | IDO1, IDO2, INMT | CYP2D6 1186/4885CA1 949/4885CA2 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.